Dec 18, 2015 by Brian Orelli, PhDPacific Biosciences of California's Stock Move Is CertifiableA double-digit jump on no news.
Dec 15, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Intl Inc Is Sitting at the Corner of Happy and Healthy TodayA deal with Walgreens helps boost investors' confidence in the drugmaker.
Dec 14, 2015 by Brian Orelli, PhDWill 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?Lots of data releases could make it so.
Dec 9, 2015 by Brian Orelli, PhDOncothyreon Inc (USA) Plunges on Confusing DataYou know management is in trouble when analysts are having trouble understanding the biotech's press release.
Dec 7, 2015 by Brian Orelli, PhDWhy XBiotech Inc. Made a U-Turn TodayPositive data despite clinical trial irregularities.
Dec 7, 2015 by Brian Orelli, PhDWhy Global Blood Therapeutics Inc Shares Are Tanking TodayThe biotech released less-than-stellar data at the American Society of Hematology meeting.
Dec 4, 2015 by Brian Orelli, PhDOrexigen Therapeutics, Inc.'s Stock Loses Weight on DowngradeThe downgrade from Well Fargo caps off a lackluster year.
Dec 3, 2015 by Brian Orelli, PhDFoamix Pharmaceuticals Ltd Hopes to Profit From Eli Lilly's and Amgen's Side EffectThe biotech gets pumped up on positive phase 2 data for FDX104.
Dec 1, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Intl Inc Is Up TodayThe drugmaker is making a comeback off its lows.
Nov 30, 2015 by Brian Orelli, PhDThere's a 0.0000000000028% Chance This Drug Doesn't WorkStatistics favor Gilead Sciences' Zydelig by a wee bit.
Nov 19, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Intl Inc Was Incentivized to Climb Higher TodayThe drug company is making efforts to keep employees around during the turbulent times.
Nov 15, 2015 by Brian Orelli, PhDA Pro Forma Profit for ISIS Pharmaceuticals, Inc.But don't get too excited: The biotech is raking in cash from partners, not by selling drugs.
Nov 15, 2015 by Brian Orelli, PhDExelixis, Inc. Earnings: Riding the MeteorThe biotech is still burning cash, but with data in hand, there's an opportunity for a solid revenue stream shortly.
Nov 15, 2015 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc. Earnings: 100% Positive (Data)Without any sales, the biotech reiterates its positive pipeline record.
Nov 9, 2015 by Brian Orelli, PhDWhy Celldex Therapeutics, Inc. Is Up for a Second Straight DayInvestors are exited about the potential to finally get some new data.
Nov 9, 2015 by Brian Orelli, PhDWhy Isis Pharmaceuticals Is More Potent TodayThe biotech presented positive data at the American Heart Association Scientific Sessions on Sunday.
Nov 8, 2015 by Brian Orelli, PhDCelldex Therapeutics, Inc. Earnings: Waiting to ACTClinical trial results from ACT IV are more important than anything the company can say about its quarterly results.
Nov 8, 2015 by Brian Orelli, PhDEmergent Biosolutions Inc.: Spinning Off, but Not Sputtering OutWhile preparing for the spinout of Aptevo Therapeutics, the biodeference company is still producing solid growth.
Nov 8, 2015 by Brian Orelli, PhDbluebird bio: ASH Puts a Damper on EarningsAbstracts for the American Society of Hematology were released a day after earnings.
Nov 7, 2015 by Brian Orelli, PhDMomenta Slowed (Temporarily)Momenta Pharmaceuticals, Inc. reports a quarter-over-quarter decrease in revenue from sales of Glatopa.
